supermusic
Established Member
- Reaction score
- 34
Kintor Pharma has announced positive Phase III results for its topical treatment KX-826 1.0% for androgenetic alopecia (Androgenetic Alopecia).
The study, conducted on 666 patients over 24 weeks, met its primary endpoint with statistically significant and clinically meaningful results. In terms of efficacy, the group using KX-826 1% twice daily showed an average increase of +15.33 hairs/cm², compared to +4.68 hairs/cm² in the placebo group. The 0.5% group also showed similar results (+14.46 hairs/cm²).
Regarding safety, the treatment was well tolerated, with no drug-related serious adverse events reported and a side effect profile comparable to placebo.
KX-826 is a topical antiandrogen that works by blocking androgen receptors directly in the scalp, with low systemic absorption, which could reduce risks compared to oral treatments like finasteride.
The company plans to submit for approval in China soon and aims to position KX-826 as a new alternative that could break the nearly 40-year treatment paradigm dominated by minoxidil and finasteride.
en.kintor.com.cn
The study, conducted on 666 patients over 24 weeks, met its primary endpoint with statistically significant and clinically meaningful results. In terms of efficacy, the group using KX-826 1% twice daily showed an average increase of +15.33 hairs/cm², compared to +4.68 hairs/cm² in the placebo group. The 0.5% group also showed similar results (+14.46 hairs/cm²).
Regarding safety, the treatment was well tolerated, with no drug-related serious adverse events reported and a side effect profile comparable to placebo.
KX-826 is a topical antiandrogen that works by blocking androgen receptors directly in the scalp, with low systemic absorption, which could reduce risks compared to oral treatments like finasteride.
The company plans to submit for approval in China soon and aims to position KX-826 as a new alternative that could break the nearly 40-year treatment paradigm dominated by minoxidil and finasteride.
Phase III KX-826 Tincture 1.0% For AGA Reached Primary Endpoint-Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited Focusing on the development and industrialization of potential "best-in-class" and "first-in-class" innovative drugs.